	US 12,297,467 B2
	Lipid-encapsulated dual-cleaving endonuclease for DNA and gene editing
David R. Edgell, London (CA); Thomas A. McMurrough, London (CA); Brent E. Stead, Toronto (CA); and Odisho K. Israel, Toronto (CA)
Assigned to SPECIFIC BIOLOGICS INC., Ontario (CA)
Filed by SPECIFIC BIOLOGICS INC., Toronto (CA)
Filed on Jun. 22, 2022, as Appl. No. 17/846,771.
Application 17/846,771 is a continuation of application No. 17/514,585, filed on Oct. 29, 2021.
Application 17/514,585 is a continuation of application No. PCT/IB2020/054229, filed on May 4, 2020.
Claims priority of provisional application 62/842,586, filed on May 3, 2019.
Claims priority of provisional application 63/019,423, filed on May 3, 2020.
Prior Publication US 2023/0016280 A1, Jan. 19, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 9/22 (2006.01); A61K 31/7088 (2006.01); A61K 38/46 (2006.01); C12N 15/11 (2006.01); C12N 15/90 (2006.01)

CPC C12N 9/22 (2013.01) [A61K 31/7088 (2013.01); A61K 38/465 (2013.01); C12N 15/11 (2013.01); C12N 15/907 (2013.01); C12N 2310/20 (2017.05); C12N 2800/80 (2013.01)]

18 Claims

1. A nuclease comprising a modified Staphylococcus aureus Cas9, wherein said modified Staphylococcus aureus Cas9 comprises an aspartic acid to glutamic acid substitution at an amino acid corresponding to position 10 of SEQ ID NO: 13, and wherein the amino acid sequence of the Staphylococcus aureus Cas9 has at least 99% sequence identity to SEQ ID NO: 13.